AZURE-outcome

A breakthrough medication in tablet form for lowering LDL cholesterol as primary and secondary prevention of cardiovascular events.

A randomized, double-blind, placebo-controlled study with two parallel groups designed to evaluate the effect of AZD0780 (larovprovstat) on major adverse cardiovascular events in patients with confirmed atherosclerotic cardiovascular disease (ASCVD) or at high risk of a first ASCVD event.

Book
examination